

Patient Name: MATSUMOTO, MIKA
Patient Address: 15 KALONG RD, GLENROY 3046
D.O.B: 3/03/1964
Medicare No.: 3451 84054 6-
Lab. Reference: 2024NI0019815-1
Addressee: DR SHRADHANAND REDDY
Sex at Birth: F
IHI No.:
Provider: capitalr
Referred by: DR SHRADHANAND REDDY
Date Requested: 15/10/2024
Date Collected: 18/10/2024
Specimen:
Subject(Test Name): BREAST / AXILLA UNILATERAL LEFT US
Clinical Information:

Patient Name: Mika Matsumoto, DOB: 03/03/1964, Date: 18/10/2024 11:40, Patient Identifier: 1561598

US BREAST OR AXILLA ONE SIDE LEFT

Clinical Notes:
Left breast lump

Findings:
Palpable mass 12 o'clock 2 cm. 9 x 9 x 8 mm with irregular margin.
Hypoechoic and taller than wide. Possible tiny calcification.

No other mass seen. No axillary adenopathy.


Conclusion:

Suspicious lesion left breast 12 o'clock. 9 mm. Report 2023 indicated 10
~~o'clock.? Same lesion~~
No significant change in size

Specialist review .? Already done

Dr Michael Gray
Radiologist
FRANZCR

Copy and paste this link to view images -
<https://connect.capitalradiology.com.au/Portal/app#patients/1561598>



Patient Name:	MATSUMOTO, MIKA MIKA		
Patient Address:	15 KALANG RD, GLENROY 3046		
D.O.B:	3/03/1964	Sex at Birth:	F
Medicare No.:	34518405461	IHI No.:	
Lab. Reference:	24-96482039-FBE-0	Provider:	DOREVITCH PATHOLOGY
Addressee:	DR SHRADHANAND REDDY	Referred by:	DR. SHRADHANAND REDDY
Date Requested:	15/10/2024	Date Performed:	17/10/2024
Date Collected:	17/10/2024	Complete:	Final
Specimen:			
Subject(Test Name):	FULL BLOOD EXAMINATION		
Clinical Information:			

FULL BLOOD EXAMINATION

HB :	129 g/L	(115-165)			($\times 10^9$ /L)
PCV:	0.40 L/L	(0.37-0.47)	*	WHITE CELL COUNT:	3.1 (4.0-11.0)
RCC:	4.10 $\times 10^{12}$	/L (3.80-5.80)	*	Neutrophils:	43% 1.3 (2.0-8.0)
MCV:	96 fL	(80-96)		Lymphocytes:	38% 1.2 (1.0-4.0)
MCH:	32 pg	(27-32)		Monocytes :	7% 0.2 (0.0-1.0)
MCHC	327 g/L	(320-360)		Eosinophils:	9% 0.3 (0.0-0.5)
RDW:	12.9 %	(11.0-16.0)		Basophils :	3% 0.1 (0.0-0.2)
				PLATELETS	: 284 (150-450)

COMMENT: Mild neutropenia.

Requested Tests : VID*, GHb*, FES*, CRP*, MBI*, LIP*, FBE

Patient Name: MATSUMOTO, MIKA MIKA
Patient Address: 15 KALANG RD, GLENROY 3046
D.O.B: 3/03/1964
Medicare No.: 34518405461
Lab. Reference: 24-96482039-GHB-0
Addressee: DR SHRADHANAND REDDY

Date Requested: 15/10/2024
Date Collected: 17/10/2024
Specimen:
Subject(Test Name): HBA1C (GLYCATED HB)
Clinical Information:

Sex at Birth: F
IHI No.:
Provider: DOREVITCH PATHOLOGY
Referred by: DR. SHRADHANAND REDDY

Date Performed: 17/10/2024
Complete: Final

BLOOD HAEMOGLOBIN A 1c

Date	Lab.No.	HBA1C %	HbA1c mmol/mol
17/10/24	96482039	5.2	33

For diagnosis of diabetes mellitus the cut off is 6.5%.

For monitoring diabetic patients use the guidelines below.

Guidelines	HbA1c%	HbA1c mmol/mol
General Target	< 7.1	< 54
Adequate	< 8.1	< 65
Suboptimal	> 8.0	> 64

Requested Tests : VID*, GHB, FES*, CRP*, MBI*, LIP*, FBE

Patient Name: MATSUMOTO, MIKA MIKA
Patient Address: 15 KALANG RD, GLENROY 3046
D.O.B: 3/03/1964
Medicare No.: 34518405461
Lab. Reference: 24-96482039-CRP-0
Addressee: DR SHRADHANAND REDDY
Sex at Birth: F
IHI No.:
Provider: DOREVITCH PATHOLOGY
Referred by: DR. SHRADHANAND REDDY
Date Requested: 15/10/2024
Date Collected: 17/10/2024
Specimen:
Subject(Test Name): C-REACTIVE PROTEIN
Clinical Information:

SERUM C-REACTIVE PROTEIN (CRP)

Date	Lab. No.	CRP	Ref Range (0-10)
17/10/24	96482039	< 1 mg/L	

Requested Tests : VID*, GHB, FES*, CRP, MBI*, LIP*, FBE



Patient Name: MATSUMOTO, MIKA MIKA
Patient Address: 15 KALANG RD, GLENROY 3046
D.O.B: 3/03/1964
Medicare No.: 34518405461
Lab. Reference: 24-96482039-FES-0
Addressee: DR SHRADHANAND REDDY

Date Requested: 15/10/2024
Date Collected: 17/10/2024
Specimen:
Subject(Test Name): IRON STUDIES
Clinical Information:

Sex at Birth: F
IHI No.:
Provider: DOREVITCH PATHOLOGY
Referred by: DR. SHRADHANAND REDDY

Date Performed: 17/10/2024
Complete: Final

SERUM IRON-STUDIES

Date: 27/05/14 16/07/19 17/10/24
Time: 10:25 08:40 09:30
Lab. No: 36060665 41492115 96482039

				Units	Ref. Range
Ferritin:	28	59	84	ug/L	(30-300)
Iron:	15	26	21	umol/L	(7-27)
Transferrin:	2.3	2.4	1.9	g/L	(2.0-3.6)
Transferrin Sat:	26	43	44	%	(13-47)

Medical professionals: Please contact a pathologist on 03 9244 0444 if required.

Method: Siemens Immunoassay

Requested Tests : VID*, GHB, FES, CRP, MBI*, LIP*, FBE

Patient Name: MATSUMOTO, MIKA MIKA
Patient Address: 15 KALANG RD, GLENROY 3046
D.O.B: 3/03/1964
Medicare No.: 34518405461
Lab. Reference: 24-96482039-VID-0
Addressee: DR SHRADHANAND REDDY
Sex at Birth: F
IHI No.:
Provider: DOREVITCH PATHOLOGY
Referred by: DR. SHRADHANAND REDDY
Date Requested: 15/10/2024
Date Collected: 17/10/2024
Specimen:
Subject(Test Name): 25 HYDROXY VITAMIN D
Clinical Information:

SERUM 25 - HYDROXY VITAMIN D

Date	Lab. No.	25 - Hydroxy Vitamin D (nmol/L)	Ref.Range (> 50)
17/10/24	96482039	<u>72</u>	

Optimal vitamin D concentrations are greater than 50 nmol/L at the end of winter and greater than 60-70 nmol/L at the end of summer.

Method: DiaSorin Liaison XL immunoassay. Note that this test cannot be used to monitor patients taking exclusively 1,25 dihydroxy Vitamin D (Calcitriol).

Requested Tests : VID, GHB, FES, CRP, MBI*, LIP*, FBE



Patient Name: MATSUMOTO, MIKA MIKA
Patient Address: 15 KALANG RD, GLENROY 3046
D.O.B: 3/03/1964
Medicare No.: 34518405461
Lab. Reference: 24-96482039-MBI-0
Addressee: DR SHRADHANAND REDDY
Sex at Birth: F
IHI No.:
Provider: DOREVITCH PATHOLOGY
Referred by: DR. SHRADHANAND REDDY
Date Requested: 15/10/2024
Date Collected: 17/10/2024
Specimen:
Subject(Test Name): GENERAL BIOCHEMISTRY
Clinical Information:

SERUM/PLASMA BIOCHEMISTRY

		Ref. Range
<u> </u> Sodium :	143 mmol/L	(135-145)
<u> </u> Potassium :	3.9 mmol/L	(3.5-5.2)
<u> </u> Chloride :	109 mmol/L	(95-110)
<u> </u> Bicarbonate :	30 mmol/L	(22-32)
<u> </u> Urea :	4.9 mmol/L	(3.0-10.0)
<u> </u> Est.GFR (mL/min) :	> 90 per 1.73sqm	(> 60)
<u> </u> Creatinine :	64 umol/L	(40-90)
<u> </u> Total Bilirubin :	18 umol/L	(< 20)
<u> </u> Ala. Aminotransferase (ALT) :	24 U/L	(< 35)
<u> </u> Asp. Aminotransferase (AST) :	25 U/L	(< 35)
<u> </u> Alkaline Phosphatase (ALP) :	67 U/L	(30-110)
<u> </u> Gamma Glutamyl Trans. (GGT) :	16 U/L	(< 35)
<u> </u> Total Protein :	64 g/L	(60-80)
<u> </u> Albumin :	40 g/L	(34-47)
<u> </u> Globulin :	24 g/L	(22-40)
<u> </u> Urate:	0.27 mmol/L	(0.11-0.42)

Requested Tests : VID, GHB, FES, CRP, MBI, LIP*, FBE

Patient Name: MATSUMOTO, MIKA MIKA
Patient Address: 15 KALANG RD, GLENROY 3046
D.O.B: 3/03/1964
Medicare No.: 34518405461
Lab. Reference: 24-96482039-LIP-0
Addressee: DR SHRADHANAND REDDY
Sex at Birth: F
IHI No.:
Provider: DOREVITCH PATHOLOGY
Referred by: DR. SHRADHANAND REDDY
Date Requested: 15/10/2024
Date Performed: 17/10/2024
Date Collected: 17/10/2024
Complete: Final
Specimen:
Subject(Test Name): LIPID STUDIES
Clinical Information:

SERUM/PLASMA LIPID STUDIES - Fasting

Total Chol:	6.0 mmol/L	(4)
Triglyceride:	0.7 mmol/L	
HDL - C:	2.1 mmol/L	
LDL - C:	3.6 mmol/L	(1.8)
NON HDL - C:	3.9 mmol/L	
Chol/HDL Ratio:	2.9	

Therapeutic targets vary depending on the patient's cardiovascular risk profile.

	T.Chol	Trig	HDL-C	LDL-C	Non HDL-C
Primary Prevention:	<4.0	<2.0	>=1.0	<2.0	<2.5
Secondary Prevention:		<2.0	>=1.0	<1.8	<2.5

National Vascular Disease Prevention Alliance Guidelines 2012.
<http://strokefoundation.com.au>

National Heart Foundation Guidelines 2012.
<http://www.heartfoundation.org.au>

Note: The Chol/HDL ratio reflects changes in VLDL, LDL and HDL, with high values indicating an increased risk of atherosclerosis.
 Target values < 3.5 are sometimes recommended for people with known vascular disease or others at high risk.

Target LDL is less than 2.0 mmol/L in people with

- A personal or strong family history of vascular disease
- Diabetes
- Aboriginal or Torres Strait Islander ancestry

Requested Tests : VID, GHB, FES, CRP, MBI, LIP, FBE